14-3-3ζ overexpression defines high risk for breast cancer recurrence and promotes cancer cell survival

Cancer Research

Volumn 69, Issue 8, 2009, Pages 3425-3432

  Neal, Christopher L ^a   Yao, Jun ^a   Yang, Wentao ^a,b   Zhou, Xiaoyan ^a,b   Nguyen, Nina T ^a   Lu, Jing ^a   Danes, Christopher G ^a   Guo, Hua ^a   Lan, Keng Hsueh ^a,c   Ensor, Joe ^a   Hittelman, Walter ^a   Hung, Mien Chie ^a   Yu, Dihua ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

SMALL INTERFERING RNA; STRATIFIN; PROTEIN 14 3 3; TUMOR MARKER;

ANCHORAGE INDEPENDENT GROWTH; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER RECURRENCE; CANCER RISK; CELL SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOWN REGULATION; HUMAN; HUMAN CELL; INTRADUCTAL CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR XENOGRAFT; BIOSYNTHESIS; BREAST TUMOR; CELL ADHESION; CELL GROWTH; FEMALE; GENE AMPLIFICATION; GENETICS; METABOLISM; MITOCHONDRION; PATHOLOGY; PHYSIOLOGY; RISK FACTOR; TUMOR CELL LINE; TUMOR RECURRENCE;

14-3-3 PROTEINS; APOPTOSIS; BREAST NEOPLASMS; CELL ADHESION; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; GENE AMPLIFICATION; HUMANS; MITOCHONDRIA; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 65949124697     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-2765     Document Type: Article

References (34)

1. Chatterjee SK, Zetter BR. Cancer biomarkers: knowing the present and predicting the future. Future Oncol 2005; 1: 37-50.
2. Press MF, Pike MC, Chazin VR. et al. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 1993: 53: 4960-70. (Pubitemid 23326194)
3. Aitken A. 14-3-3 proteins on the MAP. Trends Biochem Sci 1995; 20: 90-7.
4. Aitken A. 14-3-3 proteins: a historic overview. Semin Cancer Biol. 2006; 16: 162-72. (Pubitemid 43796128)
5. Muslin Aj, Tanner JW, Allen PM, Shaw AS. Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine. Cell 1996; 84: 889-97. (Pubitemid 26106858)
6. van Hemert MJ, Steensma HY, van Heusden GP. 14-3-3 proteins: key regulators of cell division, signaling and apoptosis. Bioessays 2001; 23: 936-46. (Pubitemid 32972693)
7. Tzivion G, Gupta VS, Kaplun L, Balan V. 14-3-3 proteins as potential oncogenes. Semin Cancer Biol. 2006: 16: 203-13. (Pubitemid 43810260)
8. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70. (Pubitemid 30046295)
9. Porter GW, Khuri FR, Fu H. Dynamic 14-3-3/client protein interactions integrate survival and apoptotic pathways. Semin Cancer Biol. 2006; 16: 193-202. (Pubitemid 43796125)
10. Suzuki H, Itoh F, Toyota M, Kikuchi T, Kakiuchi H, Imai K. Inactivation of the 14-3-3 σ gene is associated with 5' CpG island hypermethylation in human cancers. Cancer Res 2000; 60: 4353-7. (Pubitemid 32103610)
11. Danes CG, Wyszomierski SL, Lu J, Keal CL, Yang W, Yu D. 14-3-3 ζ down-regulates p53 in mammary epithelial cells and confers luminal filling. Cancer Res 2008; 68: 1760-7.
12. Tan M, Yao J, Yu D. Overexpression of the c-erbB-2 gene enhanced intrinsic metastatic potential in human breast cancer cells without increasing their transformation abilities. Cancer Res 1997; 57: 1199-205. (Pubitemid 27138623)
13. Tan M, Jing T, Lan KH. et al. Phosphorylation on tyrosine-15 of p34 (Cdc2) by ErbB2 inhibits p34 (Cdc2) activation and is involved in resistance to taxol-mdueed apoptosis. Mol. Cell 2002; 9: 993-1004. (Pubitemid 34626669)
14. Tan M, Lan K-H, Yao J. et al. Selective inhibition of ErbB2-overexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting signal transducers and activators of transcription 3-blocking peptide. Cancer Res 2006; 66: 3764-72.
15. Cianfrocca M, Goldstein LJ. Prognostic and predictive factors in early-stage breast cancer. Oncologist 2004; 9: 606-16. (Pubitemid 39546402)
16. Kattan MW. Evaluating a new markers predictive contribution. Clin. Cancer Res 2004; 10: 822-4. (Pubitemid 38198879)
17. Uhlen M, Bjorling E, Agaton C. et al. A human protein atlas for normal and cancer tissues based on antibody proteomies. Mol. Cell Proteomics 2005; 4: 1920-32. (Pubitemid 41830186)
18. Solomon E, Borrow J, Goddard AD. Chromosome aberrations and cancer. Science 1991; 254: 1153-60. (Pubitemid 21917440)
19. Pollack JR, Sorlie T, Perou CM. et al. Microarray analysis reveals a major direct role of DKA copy number alteration in the transcriptional program of human breast tumors. Proc. Natl. Acad. Sci. U S A 2002; 99: 12963-8.
20. Slamon DJ, Godolphin W, Jones LA. et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-12. (Pubitemid 19147683)
21. Escot C, Theillet C, Lidereau R. et al. Genetic alteration of the c~myc protooncogene (MYC) in human primary breast carcinomas. Proc. Natl. Acad. Sci. U S A 1986; 83: 4834-8. (Pubitemid 16075494)
22. Miller FR, Soule HD, Tait L. et al. Xenograft model of progressive human proliferative breast disease. J. Natl Cancer Inst 1993; 85: 1725-32. (Pubitemid 23320842)
23. Felsher DW. Reversibility of oncogene-induced cancer. Curr Opin Genet Dev 2004; 14: 37-42. (Pubitemid 38167475)
24. Brunei A, Bonni A, Zigmond MJ. et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999; 96: 857-68. (Pubitemid 29165088)
25. Fan T, Li R, Todd NW. et al. Up-regulation of 14-3-3 ζ in lung cancer and its implication as prognostic and therapeutic target. Cancer Res 2007; 67: 7901-6. (Pubitemid 47281386)
26. Rogers CE, Loveday RL, Drew PJ, Greenman J. Molecular prognostic indicators in breast cancer. Eur J. Surg Oncol 2002; 28: 467-78. (Pubitemid 35446773)
27. Heidenblad M, Lindgren D, Jonson T. et al. Tiling resolution array CGH and high density expression profiling of urothelial carcinomas delineate genomic amplicons and candidate target genes specific for advanced tumors. BMC Med Genomics 2008; 1: 3.
28. Qi W, Martinez JD. Reduction of 14-3-3 proteins correlates with increased sensitivity to killing of human lung cancer cells by ionizing radiation. Radiat Res 2003; 160: 217-23. (Pubitemid 36897502)
29. Li Z, Zhao J, Du Y. et al. Down-regulation of 14-3-3ζ suppresses anchorage-independent growth of lung cancer cells through anoikis activation. Proc. Natl. Acad. Sci. U S A 2008; 105: 162-7.
30. Frasor J, Chang EC, Komm B. et al. Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. Cancer Res 2006; 66: 7334-40. (Pubitemid 44197716)
31. Ferguson AT, Evron E, Umbricht CB. et al. High frequency of hypermethylation at the 14-3-3 σ locus leads to gene silencing in breast cancer. Proc Matl Acad Sci U S A 2000; 97: 6049-54. (Pubitemid 30367521)
32. Yang H, Wen YY, Zhao R. et al. DNA damage-induced protein 14-3-3 σ inhibits protein kinase B/Akt activation and suppresses Akt-activated cancer. Cancer Res 2006; 66: 3096-105.
33. Chaudhri M, Scarabel M, Aitken A. Mammalian and yeast 14-3-3 isoforms form distinct patterns of dimers in vivo. Biochem Biophys Res Commun 2003; 300: 679-85. (Pubitemid 36268890)
34. Verdoodt B, Benzinger A, Popowicz GM, Holak TA, Hermeking H. Characterization of 14-3-3 σ dimerization determinants: requirement of homodimerization for inhibition of cell proliferation. Cell Cycle 2006; 5: 2920-6.